The recommendations represent an update of 2018 consensus-based recommendations from the SHARE Initiative and the 2019 American College of Rheumatology/Arthritis Foundation guideline.
JAK inhibitors discontinuation and retention rates were similar to those for biologic disease-modifying antirheumatic drugs in large Canadian RA data sets.